{"id":"https://genegraph.clinicalgenome.org/r/8745782b-887b-497f-abf8-b611f0b49156v1.3","type":"EvidenceStrengthAssertion","dc:description":["*EED* was first reported in relation to autosomal dominant Cohen-Gibson syndrome in 2015 (Cohen et al., PMID: 25787343). Cohen-Gibson syndrome is an overgrowth disorder characterized by increased somatic growth parameters with neonatal onset and variable intellectual disability. Affected individuals have dysmorphic facial features, advanced bone age, and skeletal abnormalities, including flaring of the metaphyses of the long bones, large hands with long fingers and camptodactyly, and often scoliosis or cervical spine anomalies. Other features may include hypotonia, difficulty walking due to skeletal anomalies, and umbilical hernia (PMID: 27868325). \n\nNine variants (8 missense and one insertion-deletion) that primarily arise *de novo* or are assumed *de novo* have been reported in 11 probands in 8 publications (PMIDs: 25787343, 27193220, 27868325, 28229514, 28475857, 29410511, 30793471, 30858506) and are included in this curation. Though all variants reported to date have been missense, loss of function has been postulated as the mechanism of disease as a functional copy of *EED* is essential for proper EZH2-mediated methyltransferase activity at H3K27 via the polycomb repressive complex 2 (PRC2). This was supported by western blotting of H3K27me3 as a marker of PRC2 methyltransferase activity; wild-type *EED* rescued normal levels of H3K27me3 whereas at least two reported missense variants failed to do so (PMID: 28229514). This gene-disease relationship is also supported by biochemical function in the PRC2 which maintains gene silencing to play a role in neurogenesis and embryogenesis, and protein interaction with EZH2 to support methyltransferase activity (PMIDs: 9584199, 15225548,  27578866).\n\nIn summary, there is moderate evidence to support this gene-disease relationship. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on December 6, 2022 (SOP Version 9). ","EED was first reported in relation to autosomal dominant Cohen-Gibson syndrome in 2015 (Cohen et al., PMID: 25787343). Cohen-Gibson syndrome (COGIS) is an overgrowth disorder characterized by increased somatic growth parameters with neonatal onset and variable intellectual disability. Affected individuals have dysmorphic facial features, advanced bone age, and skeletal abnormalities, including flaring of the metaphyses of the long bones, large hands with long fingers and camptodactyly, and often scoliosis or cervical spine anomalies. Other features may include hypotonia, difficulty walking due to skeletal anomalies, and umbilical hernia (Cooney et al., 2017). Nine variants (missense and one insertion-deletion) that primarily arise de novo or assumed de novo have been reported in 11 probands in 8 publications (PMIDs: 25787343, 27193220, 27868325, 28229514, 30793471, 29410511, 30793471, 30858506) and are included in this curation. Though all variants reported to date have been missense, loss of function has been postulated as the mechanism of disease as a functional copy of EED is essential for proper EZH2-mediated methyltransferase activity at H3K27 via the polycomb repressive complex 2 (PRC2). This was supported by western blotting of H3K27me3 as a marker of PRC2 methyltransferase activity, through which wild-type EED rescued normal levels of H3K27me3 whereas at least two reported missense variants failed to do so (PMID: 28229514). This gene-disease relationship is also supported by expression throughout the brain, biochemical function in the PRC2 which maintains gene silencing to play a role in neurogenesis and embryogenesis, and protein interaction with EZH2 to support methyltransferase activity (PMIDs: 9584199, 15225548, 27578866, 29415247). In summary, there is moderate evidence to support this gene-disease relationship. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged. This classification was approved by the ClinGen ID/Autism Gene Curation Expert Panel on December 6, 2022 (SOP Version 9). "],"dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/8745782b-887b-497f-abf8-b611f0b49156","GCISnapshot":"https://genegraph.clinicalgenome.org/r/44531e19-7957-424f-81e9-fc455095f14a","calculatedEvidenceStrength":"Moderate","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/44531e19-7957-424f-81e9-fc455095f14a_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2025-08-04T13:20:52.610Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/44531e19-7957-424f-81e9-fc455095f14a_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":["2022-12-06T19:00:00.000Z","2022-12-05T23:00:00.000Z"],"role":"Approver"}],"curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/44531e19-7957-424f-81e9-fc455095f14a_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7ca05dac-e30d-4863-b052-bffd55247d9f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7ca05dac-e30d-4863-b052-bffd55247d9f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29410511","allele":{"id":"https://genegraph.clinicalgenome.org/r/8bcd4d87-ad12-48a3-a6ae-879f0b3415a9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003797.5(EED):c.917_919delinsCGG (p.Arg306_Asn307delinsThrAsp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573332257"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/29f50d98-2883-4904-a782-269f2b19745d","type":"EvidenceLine","dc:description":"This variant was upgraded due to its recurrence in COG0877 from Tatton-Brown, but both cases are de novo.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/29f50d98-2883-4904-a782-269f2b19745d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30858506","allele":{"id":"https://genegraph.clinicalgenome.org/r/ce355769-0707-4103-b877-adbfc965af0e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003797.5(EED):c.581A>G (p.Asn194Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA382004235"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/41c001a4-e9ce-4994-af99-47bc4b8c9453","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/41c001a4-e9ce-4994-af99-47bc4b8c9453_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27193220","allele":{"id":"https://genegraph.clinicalgenome.org/r/72de479d-1d00-4eee-9454-d73bdf5d9a3d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003797.5(EED):c.772C>T (p.His258Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA382004703"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6f7af144-f7ed-4e77-8ab9-9613cf5c91c1","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6f7af144-f7ed-4e77-8ab9-9613cf5c91c1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30858506","allele":{"id":"https://genegraph.clinicalgenome.org/r/3747d81d-00f8-4c3d-8d0f-0e5b2f45536c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003797.5(EED):c.773A>T (p.His258Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA382004706"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/997d2a86-807b-43b3-b739-51708afb9cd7","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/997d2a86-807b-43b3-b739-51708afb9cd7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28475857","allele":{"id":"https://genegraph.clinicalgenome.org/r/7de3ec2d-5c72-428c-a8a2-30b970a6e880","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003797.5(EED):c.706A>G (p.Arg236Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA382004529"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/69b290c4-b515-4526-91f9-849c4562eac2","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/69b290c4-b515-4526-91f9-849c4562eac2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28229514","allele":{"id":"https://genegraph.clinicalgenome.org/r/1a35710a-872c-4075-a065-ff038f479cb7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003797.5(EED):c.707G>C (p.Arg236Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA382004532"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/69b290c4-b515-4526-91f9-849c4562eac2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The level of H3K27me3 was determined by western blotting as a marker of PRC2 methyltransferase activity. Increased H3K27me3 signals were observed after wild-type EED or SUZ12 transfection (rescue), whereas the variant failed to rescue and produced similar levels of H3K27me3 as the mock transfections. These results of reduced H3K27me3 levels indicate that the missense mutations found here might lead to PRC2 loss-of-function, although other functional aspects of the PRC2 (e.g., a measurement of H3K27me1 and H3K27me2 levels, an evaluation of interaction with cofactor of PRC2 and so on) were not examined.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/e3bc409c-cc39-4d11-95af-7e2b618e017b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e3bc409c-cc39-4d11-95af-7e2b618e017b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30793471","allele":{"id":"https://genegraph.clinicalgenome.org/r/5f9efe72-54ad-4af5-8de7-d44e139c4fa5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003797.5(EED):c.710A>G (p.Asp237Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA382004540"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/bd1c47ba-ebd8-42c9-82a9-a6971d35db65","type":"EvidenceLine","dc:description":"This variant is also present in the proband from the 2016 Cohen paper as a de novo occurrence. For this reason, this case was upgraded to 0.5 points.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bd1c47ba-ebd8-42c9-82a9-a6971d35db65_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30858506","allele":{"id":"https://genegraph.clinicalgenome.org/r/72de479d-1d00-4eee-9454-d73bdf5d9a3d"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5864b4c3-c3de-4b69-b3d9-4c4e6e1b589f","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5864b4c3-c3de-4b69-b3d9-4c4e6e1b589f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27868325","allele":{"id":"https://genegraph.clinicalgenome.org/r/660283d3-643d-47b7-8c6f-43f99d0dad14","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003797.5(EED):c.904A>G (p.Arg302Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA382005025"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/c91a994c-92db-4bcd-88d2-eb58c0b1cb0b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c91a994c-92db-4bcd-88d2-eb58c0b1cb0b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28475857","allele":{"id":"https://genegraph.clinicalgenome.org/r/af5c4166-db42-4fb3-a116-3954e2456f73","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003797.5(EED):c.581A>G (p.Asn194Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1699191"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/be848850-f8ba-4f36-8471-5083a71fed75","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/be848850-f8ba-4f36-8471-5083a71fed75_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25787343","allele":{"id":"https://genegraph.clinicalgenome.org/r/b8e8180b-8566-4504-8957-294dddbcc3e6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003797.5(EED):c.906A>C (p.Arg302Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA382005030"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/be848850-f8ba-4f36-8471-5083a71fed75_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The level of H3K27me3 was determined by western blotting as a marker of PRC2 methyltransferase activity. Increased H3K27me3 signals were observed after wild-type EED or SUZ12 transfection (rescue), whereas the variant failed to rescue and produced similar levels of H3K27me3 as the mock transfections. These results of reduced H3K27me3 levels indicate that the missense mutations found here might lead to PRC2 loss-of-function, although other functional aspects of the PRC2 (e.g., a measurement of H3K27me1 and H3K27me2 levels, an evaluation of interaction with cofactor of PRC2 and so on) were not examined (PMID: 28229514)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":6.2},{"id":"https://genegraph.clinicalgenome.org/r/44531e19-7957-424f-81e9-fc455095f14a_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/44531e19-7957-424f-81e9-fc455095f14a_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/db786664-fb95-4f2b-827d-2277cb1a43a7","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9508af62-efe8-4a9a-94b5-7516a4d5d7e1","type":"Finding","dc:description":"Western blots showed core PRC2 protein, Eed expression in several brain areas at P4 as well as in SVZ-derived neurospheres. In 6-week-old brains, Eed immunofluorescence was detected in the SVZ, the striatum and cerebral cortex. All DAPI+ nuclei examined in the SVZ expressed Eed, indicating it is expressed in all cells of the lineage. Similar to Eed, PRC2 epigenetic mark H3K27me3+ nuclei were found throughout the brain. GFAP+ astrocytes in the corpus callosum and SVZ, as well as S100Î²+ niche astrocytes and ependymal cells and Dcx+ neuroblasts were all H3K27me3+.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29415247","rdfs:label":"EED Expressed in Neuroblasts","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/a2027844-13d0-436e-ae79-9c8c02000f64","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3a83c473-80fc-4c3a-aa4d-816777628b7b","type":"Finding","dc:description":"Binding to EED is essential for proper EZH2-mediated methyltransferase activity.\n\nEZH2 and EED co immunoprecipitated from extracts of U-2 OS human osteosarcoma cells. The results indicate that EZH2 and EED are in vivo part of a protein complex.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9584199","rdfs:label":"Interaction with EZH2","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/941b3dad-78e0-4e25-97fe-04992586bdba","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/79991579-2897-4f9c-b0e3-230c3a953188","type":"Finding","dc:description":"ID is can result from improper neurogenesis.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15225548","rdfs:label":"PRC2 Gene Silencing","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1.5}],"evidenceStrength":"Moderate","sequence":10955,"specifiedBy":"GeneValidityCriteria9","strengthScore":7.7,"subject":{"id":"https://genegraph.clinicalgenome.org/r/NQtwUiVgIoQ","type":"GeneValidityProposition","disease":"obo:MONDO_0060510","gene":"hgnc:3188","modeOfInheritance":"obo:HP_0000006"},"version":"1.3","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_44531e19-7957-424f-81e9-fc455095f14a-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}